Univariate analysis of clinicopathological features of cohort comparing cribriform carcinoma (CC) against non-CC carcinomas
| CC | All other cases | P value (CC vs other) | |
| n | 33 | 144 | N/A |
| Age (mean) | 63 | 67 | 0.1107 |
| M:F ratio | 0.50 | 1.15 | 0.0527 |
| AJCC stage | |||
| I | 4 (12.1%) | 34 (23.6%) | 0.0477* |
| II | 8 (24.2%) | 51 (35.4%) | |
| III | 17 (51.5%) | 54 (37.5%) | |
| IV | 4 (12.1%) | 5 (3.5%) | |
| Tumour stage | |||
| pT1 | 0 (0%) | 20 (13.9%) | 0.0128* |
| pT2 | 5 (15.2%) | 20 (13.9%) | |
| pT3 | 27 (81.8%) | 81 (56.3%) | |
| pT4 | 1 (3.0%) | 23 (16.0%) | |
| Node status | |||
| N0 | 12 (36.6%) | 86 (59.7%) | 0.0195† |
| Positive nodes | 21 (60.0%) | 58 (40.3%) | |
| Developed recurrence | 5 (15.2%) | 25 (17.4%) | 0.7602 |
| Metastasis | 8 (24.2%) | 30 (20.8%) | 0.6671 |
| Microsatellite status | |||
| Stable | 30 (90.9%) | 108 (75.0%) | 0.0331* |
| Unstable | 3 (9.1%) | 36 (25.0%) | |
| Tumour location | |||
| Right | 12 (36.4%) | 83 (57.6%) | 0.0812 |
| Transverse | 7 (21.2%) | 18 (12.5%) | |
| Left | 14 (42.4%) | 43 (29.86%) |
*P<0.05.
†P<0.05 and multivariate analysis described in text.
AJCC, American Joint Committee on Cancer.